PSA is a protein your prostate leaks into your blood. More leaks when something's off: cancer, but also a benign enlargement that comes with age, an infection, a long bike ride, or sex the night before the draw. So one number is never a verdict alone. Above 4 ng/mL carries about a one-in-four chance of any cancer and one in seven of the dangerous kind 1. It's a reason to look closer.
The European trial invited 162,000 men to a PSA every few years and cut prostate-cancer deaths by 21%, a benefit still climbing at 16 years 23. The American trial found nothing, but over 80% of its "control" men got tested anyway; modeled clean, both fit a 25 to 30% cut 4. A single one-off screen shows no benefit; the win is built across rounds 5. And most screen-found cancer is the lowest grade, near-zero lethal at 15 years 6.
Treat this as a decision, then a test. Answer three questions with a doctor first: do you want the number given the trade-offs, when do you start, and what will you do with a borderline result.
Most years, nothing happens. A blood draw at your physical, a number in the chart, a short talk. The test does quiet probability work while your life goes on.
- The year it earns itself: your PSA drifts up, you repeat it, the MRI flags a zone, a targeted biopsy finds a middling-grade cancer, and you treat in time.
- Or it goes to 4.5, the MRI is clean, no biopsy, no cancer label, and you stay on cadence. A win too.
- Either way, at 15 years you skipped both bad endings: the late-caught back-pain story, and the prostatectomy for a cancer that would never have killed you.
The fine print — when to skip it, and what people get wrong
A high PSA is not cancer — most come from an aging prostate, an infection, or a recent ride 1. And a cancer label is not a death sentence: low-risk disease is now watched, same survival 10.
Nearly every bad PSA outcome is one skipped step: a biopsy ordered without an MRI first, surgery on the lowest-grade cancer that only costs continence, or a rising number left to drift unresolved 11.
If life expectancy is under about 10 years, often men 75+ with other illness, the benefit can't arrive in time and screening turns to net harm 9. A father who died of it justifies earlier screening, never screening past your runway.
- 1Thompson IM, Pauler DK, Goodman PJ et al. (2004). Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. New England Journal of Medicine. link
- 2Schröder FH, Hugosson J, Roobol MJ et al. (2014). Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. The Lancet. link
- 3Hugosson J, Roobol MJ, Månsson M et al. (2019). A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer. European Urology. link
- 4Tsodikov A, Gulati R, Heijnsdijk EAM et al. (2017). Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Annals of Internal Medicine. link
- 5Martin RM, Donovan JL, Turner EL et al. (2018). Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA. link
- 6Klotz L, Vesprini D, Sethukavalan P et al. (2015). Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. Journal of Clinical Oncology. link
- 7Mahal BA, Gerke T, Awasthi S et al. (2022). Prostate cancer racial disparities: a systematic review by the Prostate Cancer Foundation panel. European Urology Oncology. link
- 8Kasivisvanathan V, Rannikko AS, Borghi M et al. (2018). MRI-targeted or standard biopsy for prostate-cancer diagnosis. New England Journal of Medicine. link
- 9USPSTF (2018). Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. link
- 10Hamdy FC, Donovan JL, Lane JA et al. (2023). Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine. link
- 11Eklund M, Jäderling F, Discacciati A et al. (2021). MRI-targeted or standard biopsy in prostate cancer screening. New England Journal of Medicine. link
Related in the handbook (11)
- — PSA is the asterisk on the cancer-screening lineup: discuss it first, since the harms are real.
- — A BRCA2 result changes prostate screening for men: start PSA earlier and take an elevated number more seriously.
- — Prostatitis flares can spike your PSA — worth knowing before an elevated result sends you toward a biopsy.
- — Treating prostate cancer often causes lasting erectile trouble — a big reason screening decisions deserve a real conversation.
- — Finasteride and dutasteride cut PSA by about half; note the drug before calling a prostate result reassuring.
- — A PSA test answers a cancer question, not a urinary-symptom one — many night-time trips have nothing to do with the prostate.
- — These multi-cancer blood tests are floated as an alternative to running separate screens like PSA.
- — Want a real example of why the baseline number matters? PSA screening's modest absolute benefit is it.
- — If PSA screening leads to prostate surgery, pelvic-floor training shortens the leak-recovery timeline.
- — If your prostate is the reason you're here, the real prostate questions — including when to screen — sit in a urologist's office, not the supplement aisle.
- — Before and during testosterone therapy, PSA gets watched — the hormone can stir up an existing prostate cancer.
PSA Screening for Prostate Cancer
The blood test is cheap and usually covered. Follow-up scans and biopsies, if needed, cost more but are one-offs.
One blood draw every year or two, plus a real conversation with a doctor about what the number means.
Multiple large randomized trials across decades. The modern read: screening modestly reduces prostate-cancer deaths.
A modest cut in prostate-cancer deaths — roughly one prevented per 600 men screened over 13 years. No effect on overall survival.